Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: A SEER-Medicare data analysis

Last Updated: Monday, August 11, 2025

Researchers used SEER-Medicare data to evaluate CAR T-cell therapy use among Medicare patients with diffuse large B-cell lymphoma receiving third-line or later treatment. They found that geographic and socioeconomic factors contributed to substantial disparities in CAR T-cell therapy use and that distance to the nearest CAR-T center predicted treatment probability.

Blood Advances

BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement

Blood Advances

Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: A SEER-Medicare data analysis

Journal for ImmunoTherapy of Cancer

Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach

Stem Cells Translational Medicine

Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy

Transplantation and Cellular Therapy

Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: A comprehensive analysis of real-world FAERS data

Transplantation and Cellular Therapy

Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel)

Nature Medicine

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: A phase 1 trial

Blood Advances

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

Blood Advances

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Journal of Clinical Oncology

Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma

CAR T-Cell Therapy Resource Center

Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: A SEER-Medicare data analysis

Blood Advances

BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement

Blood Advances

Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: A SEER-Medicare data analysis

Journal for ImmunoTherapy of Cancer

Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach

Stem Cells Translational Medicine

Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy

Transplantation and Cellular Therapy

Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: A comprehensive analysis of real-world FAERS data

Transplantation and Cellular Therapy

Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel)

Nature Medicine

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: A phase 1 trial

Blood Advances

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

Blood Advances

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Journal of Clinical Oncology

Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

Fast Facts #12: BCMA Targets